Chairmans statement 2009 was another record year for Croda, producing pre-tax Martin Flower Non-executive Chairman profits 10.5% up on 2008 despite one of the deepest global recessions of all time.
The constant focus on product innovation, markets and customers, combined with ongoing cost reduction, has enabled us to achieve another year of pre-tax profit growth Strong despite challenging conditions in the global economy.
funding credit of 6.4m were broadly EBITDA was Full Year Results balanced by a currency translation benefit Revenue increased by 0.6% for the year of 11.1m.
Falling debt levels and lower to 916.2m 2008: 911.1m.
This result boosted global interest rates significantly reduced was boosted by favourable currency underlying interest costs.
Continuing translation 11.8% versus 2008 that earnings per share before exceptional mitigated significant first half volume by working items increased 10.4% from 48.0p in losses in Industrial Specialities.
Falling 2008 to 53.0p in 2009. commodity prices reduced output prices in Industrial Specialities but had little Cash flow was particularly impressive capital effect on Consumer Care.
Strong EBITDA was Turnover was up 11.8% in Consumer reductions boosted by working capital reductions Care and down 9.0% in Industrial as we completed the post Uniqema Specialities as we continued to focus on reorganisation of our selling and quality of business over volume growth.
Favourable Consumer Care achieved an operating currency translation accounted for profit increase of 17.2% and in Industrial 21.7m of the reduction in net debt.
All Specialities profits declined by 35.1%.
All this meant that our key banking ratio, net the reduction came in the first half, with debt to EBITDA, fell below two times, the lack of the previous years 8.2m significantly below our covenant limit of glycerine pricing windfall adding to the three times.
A return to growth in sales and operating profit Retirement Benefits occurred in the second half.
The IAS19 pension deficit increased to Pre-tax profit was up 10.5% to 106.4m 203.5m 2008: 88.5m.
Restructuring and cost value of investments increased but the savings following the acquisition of discount rates used to calculate the Uniqema in 2006 continued throughout schemes liabilities fell, despite rising 2008 and 2009, boosting return on sales inflation expectations, due to a reduction to 13.1% despite the adverse effects of in corporate bond yields.
the recession and glycerine pricing.
A largely non-cash cost increase of 3.9m relating to share based payments as a result of the strong share price in 2009, and the reduction in the IAS19 pension 2 Restructuring During the year we announced the closures of our sites at Bromborough in Merseyside and Wilton in North Yorkshire.
Bromborough ceased production in November 2009 and its results are treated as discontinued as we have exited the specific commodity markets supplied by this site.
Wilton ceased production in January 2010.
Since nearly all products at Wilton are being transferred to other Croda sites worldwide, this business has been treated as continuing in 2009 and 2008. Dividend The Board has proposed an increase in the final dividend of 10.7% to 15.00p, taking the full year dividend to 21.50p, up 8.9% on the 19.75p paid last year.
In 2008, we stated that in future our dividend increases would be more aligned with earnings growth achieved.
This was a change to our previous policy of more modest dividend growth as we improved dividend cover.
Outlook The strong trading performance during the fourth quarter of 2009 has continued into 2010 and we are confident of achieving significant progress in the current year.
Keravis is a patented hair strengthening biopolymer derivative which acts to strengthen the hair by affecting both the biomechanical properties within the hair cortex Martin Flower and the frictional properties Chairman at the cuticle surface.
This has resulted in global success in premium hair cleansing, conditioning and styling products.
